Turing Pharmaceuticals Names Craig Rothenberg Chief Communication Officer

NEW YORK, July 29, 2015 /PRNewswire/ -- Turing Pharmaceuticals AG announced today that Craig A. Rothenberg has joined the company as its first Chief Communication Officer.

In this new role, Mr. Rothenberg will have overall responsibility for internal and external communications and will provide counsel to senior management at the company. He will report directly to Founder and Chief Executive Officer, Martin Shkreli, and will join the company's Senior Leadership Team.

"We are excited to have Craig join Turing and our senior leadership team," Mr. Shkreli said. "His deep pharmaceutical and communications experience will be a tremendous asset to us, and to me personally, as we continue to evolve Turing into a world-class biopharmaceutical company, helping to deliver on the promise of providing accessible prescription products that enhance and extend people's lives."

Mr. Rothenberg most recently was a Vice President and senior Communications leader at Johnson & Johnson, where he worked for more than 20 years. In his last role with the global healthcare leader, Rothenberg led global employee and executive communications. He brings to Turing deep experience in both external and organizational communications, as well as expertise in the areas of corporate branding, executive coaching and storytelling. While at J&J, he served on a number of the company's leadership teams and management boards.

Among his many achievements at Johnson & Johnson, Mr. Rothenberg led storytelling training for many of the company's senior executives. He also led the development of a groundbreaking program, ACCEL (The Academy for Communications Excellence and Leadership), a professional development program for the company's Communication professionals.

Mr. Rothenberg is an adjunct professor in the School of Continuing and Professional Services at New York University, where he teaches graduate-level courses in Strategic and Organizational Communications.

On his appointment, Mr. Rothenberg said, "I am excited to join Turing. The company's focus, vibrancy and commitment to advancing healthcare by developing and commercializing products that treat rare and often under-treated illnesses is something that I am keen to be a part of, and I look forward to working closely with Martin and the entire leadership team as we advance this important work."

About Turing
Turing Pharmaceuticals AG is a privately held biopharmaceutical company with offices in New York City. Turing focuses on developing and commercializing innovative treatments for serious diseases and conditions across a broad range of therapeutic areas, for which there are currently limited or no treatment options. Turing is developing ketamine for a variety of CNS indications; other current products include Syntocinon® (oxytocin nasal solution) and Vecamyl® (mecamylamine HCl tablets).  For more, visit www.turingpharma.com.

Media contact:  Allan Ripp 212-262-7477 [email protected] 
Investor Relations:  Edward Painter 646-356-5577 [email protected]

Photo - http://photos.prnewswire.com/prnh/20150729/248866 

SOURCE Turing Pharmaceuticals AG

Related Links

http://www.turingpharma.com